Equity Research, Broker Reports, and media content on UBM PLC

  • Access the latest forecasts, broker valuations, multiples, and video content from the city about UBM PLC
  • See live updates from analysts, company announcements, and other news in a personalised/single dashboard

Research, Charts & Company Announcements

Research Tree provides access to ongoing research coverage, media content and regulatory news on UBM PLC. We currently have 32 research reports from 4 professional analysts.

Date Source Announcement
20Dec16 10:40 PRN 3f Bio Wins Start-Up Innovation Challenge at Health Ingredients Europe & Natural Ingredients
20Dec16 10:40 PRN 3f Bio Wins Start-Up Innovation Challenge at Health Ingredients Europe & Natural Ingredients
19Dec16 02:00 PRN HDI 2017 Program to Feature Presentations from Microsoft, Coca-Cola, Union Pacific Railroad, Boston University, MetricNet & More
19Dec16 02:00 PRN Black Hat Asia Returns to Singapore with Robust InfoSec Research Lineup: Vulnerabilities Related to Mobile Devices, Transit Smartcards, Popular Email Clients & More
15Dec16 06:59 PRN DesignCon Announces 2017 Educational Program with Boot Camps, Tutorials & Complimentary Chiphead Theater Sessions Specific to Latest Engineering Trends & Topics
15Dec16 02:00 PRN The 2017 Medical Design & Manufacturing (MD&M) West Conference Set to Provide Insight into the Latest Breakthroughs in Medtech
14Dec16 05:06 PRN Hi Europe & Ni the Leading European Innovation HUB With a Worldwide Appeal
  • Frequency of research reports

     

  • Research reports on

    UBM PLC

  • Providers covering

    UBM PLC

Latest Content

View the latest research, videos, and podcasts for this company.

Breakfast Today

  • 14 Dec 16

The waiting is finally over. Today the markets will receive the FOMC interest rate decision, which is due to be announced around 14:00hrs ET. The fact is, however, that market pundits are so convinced that this hike, of 25bp and just the second in ten long years, will be delivered the question now has actually become more about when will the next one be, and the one after that - which is altogether is much more tricky to answer. Most US economists appear to believe Trump’s reflationary policies, not least his aggressive tax cutting proposals, will be quite dramatically simulative for consumer prices, suggesting this afternoon’s move will be followed in 2017 by, perhaps, two or three more. But unless Trump can also sustain strong employment while supporting higher wages, such benefits will be largely reserved for the asset rich classes, rather that the middle-aged workers who were the force behind his surprise election and could also limit the period of his tenure. Not that this was on the minds of traders last night, as US equities powered to another record high, with the Dow Jones creeping even closer to the 20,000 level on demand for energy shares, while yesterday’s caution on technology issues appeared forgotten by the NASDAQ which put in the strongest gain amongst the main indices. While the US$ was little changed against the international basket, yields on 2-year Treasuries rose to a six-year high in anticipation of today’s move. Asian shares gave up most of their early gains to end with just fractional movements, despite Japanese corporate sentiment rising for the first time in 18 months according to the central bank’s tankan survey. The Shanghai Composite fell modestly into the red, as international investors again worried over China’s rising war of words with the President-elect along with its authorities desperate efforts to curb capital outflows through a crack-down on unofficial banks who help people and enterprises illegally move money offshore. The UK today will release unemployment data, while later on this afternoon the US provides Retail Sales and Industrial Production data ahead of Janet Yellen’s press briefing. UK corporates due to provide earnings or trading updates include Boohoo.com (BOO.L), Dixons Carphone (DC..L), Mixcrofocus International (MCRO.L), SysGroup (SYS.L) and Wood Group (WG..L). Investors will also be hoping for more detail regarding, Sanofi, the giant French pharmaceutical group’s apparent talks regarding a possible counter-bid for biotech Actelion, countering an earlier approach from Johnson & Johnson which appears to have failed to reach agreement. Such an outcome could possibly herald the start of another phase of consolidation amongst international sector majors. This morning, the FTSE-100 is expected to be 25 points down in opening trade.